



KABRADRUGSLIMITED

CIN-L02423MP1989PLC005438

To
Department of Corporate Services,
BSE Limited,
P J Tower, Dalal Street
Mumbai-400001

12 May 2023

Sir/ Madam,

Subject: Compliance Certificate pursuant to Regulation 40(9) and 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2023

Reference: Kabra Drugs Limited (524322).

In compliance with Regulation 40(9) and 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Compliance Certificate for the half year ended March 31, 2023.

Kindly acknowledge the same.

Thanking you,

Yours faithfully

For, KABRA DRUGS LIMITED



DIRECTOR / AUTHORISED SIGNATORY



CERTIFICATE

In terms of Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI (LODR))

We have examined the relevant Books, Registers and Records relating to the transfer of securities of M/s. KABRA DRUGS LIMITED maintained by M/s. Skyline Financial Services Private Limited the Registrars and Share Transfer Agents (RTA) of the Company for the period April 1, 2022 to March 31, 2023 for the purpose of providing certificate pursuant to Regulation 40(9) of the SEBI (LODR) Regulations, 2015 and the basis of such examination and on the basis of information provided to us by the RTA and to the best of our knowledge we hereby certify that:

“No share certificate was lodged in physical form for transfer or otherwise with the Company during the period.”

Date: 11.05.2023
Place: Chennai

Narasimhan Srividhya
Practicing Company Secretary
CP No.14058
UDIN - A034428E000289441
Peer Review Certificate No:829/2020
Unique Code:P2004TN081200

NARASIMHAN SRIVIDHYA
Company Secretary in Practice
Mem No : 34428
Cop : 14058